NASDAQ:ITCI

Intra-Cellular Therapies Earning Date

USA |NASDAQ |USD

ITCI Earnings Date

|
Report Date Period Ending EPS Forecast Last Quarter's EPS Last Year's EPS
Nov 8, 2021 Sep 2021 $-0.90 $-0.85 $-0.79
Report Date Period Ending Revenue Forecast Last Quarter’s Revenue Last Year’s Revenue
Nov 8, 2021 Sep 2021 $22.69M $19.01M $7.37M

Intra-Cellular Therapies's next earnings date is Monday, Nov 8, 2021 for the fiscal quarter ending Sep 2021.

ITCI Earnings Date & History Chart

ITCI Earnings & Revenue Forecast

ITCI Earnings Forecast

|
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2021 9 $-0.96 $-1.13 $-0.80
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2021 9 $-3.37 $-3.60 $-3.19
Dec 2022 8 $-2.45 $-3.11 $-1.41

ITCI Earnings Revision Trend

|
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Dec 2021 0 / 1 $-0.97 $-0.93 $-0.91
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Dec 2021 0 / 1 $-3.38 $-3.24 $-3.22
Dec 2022 0 / 1 $-2.36 $-2.04 $-2.02

ITCI Revenue Forecast

|
Period End # of Analysts Revenue Forecast Low Revenue Forecast High Revenue Forecast
Dec 2021 9 $28.92M $26.60M $32.50M
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2021 9 $87.41M $84.60M $91.45M
Dec 2022 8 $264.57M $198.30M $313.50M

ITCI Earnings Date & Revenue History

ITCI Earnings History

|
Show More
Show More

ITCI Revenue History

|
Show More
Show More

Intra-Cellular Therapies Next Earnings Date & Report

ITCI Next Earnings Date & Report Preview: Sep 2021 (FQ)

ITCI's next earnings date is Monday, Nov 8, 2021 for the fiscal quarter ending Sep 30, 2021.

According to 9 analysts, the average EPS estimation for Intra-Cellular Therapies's next quarterly earnings is $-0.90, with a low EPS estimation of $-0.99, and a high estimation of $-0.81.

Over the last 1 month, EPS estimates have seen 0 upward revisions and 1 downward. The EPS 1 month trend is $-0.91, the last 2 month trend is $-0.85, and the 3 month trend is $-0.85.

Based on 8 analysts, the average revenue estimation is $22.69M, with a low revenue estimation of $20.90M, and a high estimation of $24.68M.

Intra-Cellular Therapies Previous Earnings Dates & Reports

ITCI Previous Earnings Date & Report Recap: Jun 2021 (FQ)

Intra-Cellular Therapies's previous earnings date was Aug 9, 2021 for its fiscal quarter ended Jun 30, 2021.

ITCI's earnings per share (EPS) was $-0.85, missing the consensus analysts forecast of $-0.81 by -5.16%.

The EPS was lower than the previous fiscal quarter (Mar 2021) by 30.77%, and higher than the same period a year before (Jun 2020) by -11.46%.

Revenues were $19.01M, worse than the forecast of $20.05M by -5.19%, up by 22.00% from the previous quarter , and up by 896.88% from the same period last year.

The company reported a net income of $-68.74M.

Free cash flow for the quarter was $-59.34M , compared to $-47.77M last quarter and $-47.02M a year before.

ITCI ended the quarter with $27.28M in total debt, a decrease of -3.28% compared to the previous quarter, and an increase of 8.56% compared to the same quarter a year before.

ITCI Previous Earnings Date & Report Recap: Dec 2020 (FY)

Intra-Cellular Therapies's previous annual earnings date was Feb 25, 2021 for its fiscal year ended Dec 31, 2020.

ITCI's earnings per share (EPS) was $-3.24, beating the consensus analysts forecast of $-3.33 by -2.70% , and lower than the previous year's EPS (Dec 2019) by 20.90%.

Revenues were $22.53M, better than the forecast of $22.30M by 1.03%, and up by 37071.49% from previous year's revenue.

The company reported a net income of $-227.01M.

Intra-Cellular Therapies reported a free cash flow of $-230.34M for its fiscal year, compared to $-128.68M a year ago.

The company ended the fiscal year with $29.14M in total debt, an increase of 25.92% compared to the previous year.